Medidata has promised to review its financial controls after fraudsters made away with $4.8 million. Midlevel employees in the eClinical company's finance department reportedly made the transfer to an overseas bank account after receiving a request for $4.8 million.
CRO magnate Icon and and eClinical outfit Medidata are pooling their resources to offer a combined platform for patient-reported outcomes in clinical trials, touting their technology as faster and more effective in surveying participants.
Medidata is providing the underlying technology, while Icon is contributing its pre-validated surveys.
With some biopharma still wary of moving their data into the cloud and the rest seeking vendors with solid cybersecurity credentials, Medidata has tapped Sumo Logic and The Herjavec Group (THG) to bolster its defenses. The new system uses machine-learning algorithms to identify threats.
Cloud-based data magnate Medidata has signed a deal with TransCelerate BioPharma, a consortium of the world's largest drugmakers, to modernize the way the industry conducts clinical trials.
The potential cost savings generated by risk-based monitoring of clinical trials has led some to tip it as a way to significantly streamline pharma's flabby studies. And that potential has lured tech providers, with Medidata and Parexel both advancing their claims on the market this week.
Having already been hit by the March selloff of biotech and tech shares, Medidata's stock sunk lower still last week after first-quarter results disappointed Wall Street. This week the eClinical provider had better news, with Sanofi signing up to use its risk-based monitoring technology.
Cloud-based eClinical outfit Medidata swung to 21% revenue growth in the first quarter, and, after hitting a record value in billings, the New York company is expecting sales to keep rolling in 2014.
CRO Theorem Clinical Research has expanded its partnership with eClinical provider Medidata, tapping technology that will allow it to capture data directly from patients.
Over the past few years Medidata has frequently spoken of its efforts to grow sales of its Rave electronic data capture (EDC) platform by pinching clients competitors, notably Oracle. Now, having expanded its relationship with Alcon, Medidata is looking to make inroads with Novartis.